Achieve Life Sciences Inc (FRA:SP4P)

€ 3.595 -0.17 (-4.52%) Market Cap: 124.64 Mil Enterprise Value: 92.93 Mil PE Ratio: 0 PB Ratio: 4.14 GF Score: 40/100

Q3 2024 Achieve Life Sciences Inc Earnings Call Transcript
Nov 07, 2024

€4.48 (+7.83%)

Earnings
Q2 2024 Achieve Life Sciences Inc Earnings Call Transcript
Aug 13, 2024

€3.87 (+1.18%)

Earnings
Q4 2023 Achieve Life Sciences Inc Earnings Call Transcript
Mar 28, 2024

€4.12 (-0.96%)

Earnings
Q3 2023 Achieve Life Sciences Inc Earnings Call Transcript
Nov 09, 2023

€3.94 (+1.55%)

Earnings
Q2 2023 Achieve Life Sciences Inc Earnings Call Transcript
Aug 15, 2023

€4.74 (-1.25%)

Earnings
Achieve Life Sciences Inc at LD Micro Invitational Conference Transcript
Jun 07, 2023
Achieve Life Sciences Inc ORCA-3 Conference Call Transcript
May 23, 2023
Q1 2023 Achieve Life Sciences Inc Earnings Call Transcript
May 09, 2023

€7.85 (+0.64%)

Earnings
Achieve Life Sciences Inc Phase 2 ORCA-V1 Trial Results Call Transcript
Apr 20, 2023
Q4 2022 Achieve Life Sciences Inc Earnings Call Transcript
Mar 16, 2023

€4.23 (+1.20%)

Earnings
Q3 2022 Achieve Life Sciences Inc Earnings Call Transcript
Nov 14, 2022

€2.03 (+1.86%)

Earnings
Q2 2022 Achieve Life Sciences Inc Earnings Call Transcript
Aug 11, 2022

€5.16 (+6.39%)

Earnings
Achieve Life Sciences Inc Annual Shareholders Meeting Transcript
May 31, 2022
Q1 2022 Achieve Life Sciences Inc Earnings Call Transcript
May 12, 2022

€5.91 (-8.16%)

Earnings
Achieve Life Sciences Inc Clinical Development Update Call Transcript
Apr 27, 2022
Q4 2021 Achieve Life Sciences Inc Earnings Call Transcript
Mar 10, 2022

€6.1 (-1.61%)

Earnings
Achieve Life Sciences Inc at Issuer Direct Winter Wonderland Best Ideas Investor Conference (Virtual) Transcript
Feb 08, 2022
Q2 2021 Achieve Life Sciences Inc Earnings Call Transcript
Aug 12, 2021

€6.5 (+7.44%)

Earnings
Q4 2020 Achieve Life Sciences Inc Earnings Call Transcript
Mar 11, 2021

€9.6 (-1.54%)

Earnings
Q2 2019 Achieve Life Sciences Inc Earnings Call Transcript
Aug 08, 2019

€30.6

Earnings

Achieve Life Sciences Inc Phase 2 ORCA-V1 Trial Results Call Transcript

Apr 20, 2023 / 12:30PM GMT

Release Date Price: €5.9 (-11.94%)

Transcript

Operator

Greetings, and welcome to the Achieve Life Sciences ORCA-V1 Top Line Clinical Trial Results Conference Call. (Operator Instructions) As a reminder, this conference is being recorded.

I would now like to turn the conference over to your host, Jaime Xinos, Executive Vice President of Achieve. Please go ahead.

Jaime Xinos

Achieve Life Sciences, Inc. - EVP of Commercial

Thank you, operator, and thank you to everyone for joining the call. Today from achieve, we have John Bencich, Chief Executive Officer; Dr. Cindy Jacobs, President and Chief Medical Officer; and Rick Stewart, Achieve Co-Founder and Chairman of the Board of Directors.

I'd like to remind everyone that today's conference call contains forward-looking statements based on current expectations. These statements are only predictions, and actual results may vary materially from those projected. Please refer to Achieve documents available on our website and filed with the SEC concerning factors that could affect the company.

I will now turn the call over to John.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.